Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Arbutus Biopharma Corp

ABUS ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: STRONG BUY

Last Close

$4.67

▲ +1.97%

Market Cap $923.95M · Vol 438.32K

Key Metrics

P/E Ratio

5.96

FWD: 20.08

Market Cap

$923.95M

Small Cap

Div Yield

N/A

EPS Growth

+517.22%

YoY

RSI (14)

62.26

Momentum

Beta

0.61

vs Market

52W High

$5.38

13.12% below

52W Low

$3.31

41.09% above

Volume

438.32K

Avg 570.56K

P/B

12.09

Price-to-book

ROE

N/A

Return on equity

Free Float

79.57%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Arbutus Biopharma Corp (ABUS) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ABUS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.86%

+1.30%

+7.36%

+17.34%

YTD

-2.91%

+38.58%

+134.67%

+52.12%

Financials & Valuation

TTM · Annual

Total Revenue	$14.08M
Net Income	$-33,501,000.00
Revenue Growth (YoY)	-90.56%
Gross Margin	100.00%
Operating Margin	-192.08%
Net Profit Margin	-237.88%
ROE	N/A
ROA · ROIC	-29.60% · N/A

P/E Ratio	5.96
Forward P/E (FY1)	20.08
PEG Ratio	N/A
P/S	65.44
P/B	12.09
P/FCF	N/A
EPS Growth	+517.22%
Outstanding Shares	197.85M

Technical Indicators

50-Day SMA	$4.54
200-Day SMA	$4.46
RSI (14)	62.26
Beta	0.61
52-Week High	$5.38
52-Week Low	$3.31

Volume Today	438.32K
Avg Daily Volume (30D)	570.56K
Relative Volume	0.77x
Volatility (10D)	29.05
Volatility (30D)	42.67
Free Float	79.57%

Analyst Consensus

STRONG BUY

Current Price $4.67

Mean Target $5.50

52W Low$3.31 52W High$5.38

Current

Target

$3.31 $5.38

Current Analyst target

+17.77% upside potential · 1 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001S6RSK0

ISINCA03879J1003

CountryCanada

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 9, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease. The Company is developing imdusiran (AB-729), its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). Its HBV product pipeline includes Imdusiran and AB-101. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for. PD-L1 inhibitors complement its pipeline of agents and could potentially be a part of a combination therapy for the treatment of HBV by reawakening the immune system.